Q2 FY2026 Earnings2Q26 results beat consensus estimates on both top and bottom lines, with record revenue of $1.21B (+16% YoY) vs. $1.11B expected. Non-GAAP Adjusted EPS reached $5.71, supported by strong commercial execution in Xywav (+13% YoY) and Epidiolex (+16% YoY), as well as a significant $106M contribution from Zepzelca. Management significantly raised FY26 revenue guidance to $4.60B–$4.75B, well above previous ranges, signaling sustained momentum in the oncology and sleep franchises.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Jazz Pharma(JAZZ) the Revenue is 1.208 B (+15.55%), Beat estimate;the EBIT is 508.1 M (+222.9%), Miss estimate;the EPS is 2.78 (+123.7%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
1.21B15.55%
1.11B6.57%
+0.09B8.98%
EBITMiss expectations
0.51B222.93%
0.51B223.66%
-0.00B0.73%
EPSMiss expectations
2.78123.68%
3.1825127.11%
-0.40253.43%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf